SCHEMBL23601905

SCHEMBL23601905

CN(c1cccc(-c2ccc(C(F)(F)F)cc2)c1)c1nc2nncn2c2cc(Cl)ccc12

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FNTA P49354 2/20 0.40
FNTB P49356 2/20 0.40
MAT2A P31153 6/20 0.33
CYP1A2 P05177 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NLRP3 Q96P20 1/20 0.33
SCN9A Q15858 1/20 0.32
TP53 P04637 1/20 0.32
MAPT P10636 1/20 0.32
ABCG2 Q9UNQ0 1/20 0.32
KIF11 P52732 1/20 0.32
TRPA1 O75762 2/20 0.32
PRMT5 O14744 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23577102 0.94 FNTA (0.41) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL31229690 0.94 FNTA (0.41) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL23601661 0.92 FNTA (0.39) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL29909922 0.92 FNTA (0.41) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL23577059 0.92 FNTA (0.41) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL29909768 0.91 FNTA (0.40) FNTAFNTBMAT2ACYP1A2KDM4E
SCHEMBL23601235 0.91 FNTA (0.40) FNTAFNTBMAT2ACYP1A2KDM4E
SCHEMBL31169406 0.90 FNTA (0.40) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL23600548 0.90 FNTA (0.40) FNTAFNTBMAT2ACYP1A2TP53
SCHEMBL23577794 0.90 FNTA (0.36) FNTAFNTBMAT2ACYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 US disclosed
WO-2021130638-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES, INC. (JP) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK FNTA 968/4885FNTB 743/4885MAT2A 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.